普門科技(688389.SH):空氣波壓力循環治療系統取得醫療器械註冊證
格隆匯3月31日丨普門科技(688389.SH)公佈,控股子公司重慶普門創生物技術有限公司於近期收到了重慶市藥品監督管理局頒發的《中華人民共和國醫療器械註冊證》,產品名稱:空氣波壓力循環治療系統。上述取得註冊證的空氣波壓力循環治療系統,專門為治療淋巴和靜脈血管疾病而設計,通過多腔體充氣氣囊有次序、有節律地充氣膨脹擠壓、放氣,形成對肢體組織的循環加壓,達到促進靜脈迴流、加強動脈灌注、改善血液循環和淋巴循環、防止凝血因子的聚集及對血管內膜的粘附,增加纖溶系統的活性,預防靜脈血栓、消除水腫。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.